An easy way for investors to buy protection: Consider value stocks with high dividend yields

Tim McIntosh of PVG Asset Management expects interest rates to fall, supporting prices for stocks in four sectors with attractive dividend payouts.

  • By Philip Van Doorn,
  • MarketWatch
  • Investing for Income
  • Investing in Stocks
  • Dividend-Paying Stocks
  • Investing for Income
  • Investing in Stocks
  • Dividend-Paying Stocks
  • Investing for Income
  • Investing in Stocks
  • Dividend-Paying Stocks
  • Facebook.
  • Twitter.
  • LinkedIn.
  • Google Plus
  • Print

Financial headlines are usually focused on high-flying tech stocks or dire warnings of a market crash.

We cannot predict when any big market drop will happen, but diversifying part of your portfolio away from the big tech names that weigh so heavily on indexes can lower your investment risk. And high-dividend yields make it much easier to wait for a stressed market to recover.

The S&P 500 Index (.SPX) has returned 8% this year. The FAANG stocks — Facebook (FB), Amazon.com (AMZN), Apple (AAPL), Netflix (NFLX), and Google holding company Alphabet (GOOG) (GOOGL) — have a combined value of $3.39 trillion and make up 14% of the benchmark index’s market value, according to FactSet.

So even if you are diversified in an index fund, you have a lot of eggs in the FAANG basket. This year Facebook is down 5% (which may be no surprise with all its controversy), but Amazon has returned 71%, Apple 36%, Netflix 78% and Alphabet’s class C shares 13%.

Tim McIntosh is a portfolio manager with PVG Asset Management who runs the firm’s Large-Cap Value portfolio, which has a five-star rating (the highest) from Morningstar. PVG is headquartered in Centennial, Colo., and has about $275 million in assets under management for private clients. McIntosh is based in Clearwater, Fla., and has run the large-cap value strategy since 2005, initially for SIPCO, which was merged into PVG in 2016.

When selecting companies for the portfolio, McIntosh looks at a combination of factors, including dividend growth, low price-to-book or price-to-sales ratios and low volatility for share prices.

Those factors are combined with a sector-driven strategy, as McIntosh considers the timing of the U.S. economic cycle and which sectors are most likely to perform best.

In an interview Sept. 6, McIntosh acknowledged that value-investing strategies “have substantially underperformed over time,” and said, “over the past eight years, the technology and consumer discretionary sectors have outperformed the other sectors.”

“Hopefully it’s value’s turn,” he said. “Value tends perform well in early and late economic cycles. We appear to be in the seventh or eighth inning of this growth cycle.”

McIntosh said the likelihood of a recession in the next three to five years is high, and he predicted that yields on 10-year U.S. Treasury notes (TMUBMUSD10Y), “are not headed above 3%.” He went so far as to predict that the yield on the 10-year, which has been in a range of 2.82% to 3.00% since the end of May, “will come back down to 2.25% to 2.50%. ”If long-term interest rates hold steady or decline, it’s good news for income-producing securities because of the inverse relationship between their market values and the direction of rates. High-yielding dividend stocks, including real estate investment trusts (REITs), suffer or gain from the inverse relationship, especially when rates move quickly.

As we have seen with REITs, a growing economy can offset a temporary setback for prices, but in general, price action for the real estate and utilities sectors has been weak over the past two years. McIntosh favors those sectors now, along with the energy and health-care sectors.

He discussed one stock in each sector:

Ventas

Ventas (VTR) is a real estate investment trust that is nearly 90% invested in health care-related properties, including medical office buildings and skilled nursing and assisted living facilities. The demographics of an aging population, along with a seemingly endless flow of government money into health care bode well for the REIT’s long-term prospects.

The stock has a dividend yield of 5.27%.

The shares closed at $59.94 on Sept. 5 and have traded between $46.55 and $69.92 over the past 12 months.

McIntosh said he was continuing to add to his portfolio holdings of Ventas as it traded below $50. But he is still an enthusiast at the current price: “We think it is still undervalued. Our target price is for it to get back to $70 a share,” he said.

Duke Energy

Shares of Duke Energy (DUK), of Charlotte, N.C., have a dividend yield of 4.46%. The shares closed at $83.19 on Sept. 5 and have ranged between $71.96 and $91.80 over the past year.

“With utilities, you look for diversification, which Duke has, and you also look for dividend increases. Their increase [tends to be] about 5% a year, McIntosh said.

Occidental Petroleum

Occidental Petroleum’s stock (OXY) closed at $79.14 on Sept. 5, with a 52-week range of $59.78 and $87.67. The shares have a dividend yield of 3.94%.

McIntosh was quick to point out that while integrated oil companies, including Exxon Mobil (XOM) and Chevron (CVX), were not forced to cut their dividends after oil prices tumbled during 2014 and 2015, most companies specializing in oil exploration and production did. Occidental was an exception and in July raised its quarterly payout by a penny to 78 cents.

McIntosh said Occidental’s break-even point for its oil production to be profitable while supporting the dividend is “between $40 and $45 a barrel now, where two years ago it was about $60.” West Texas crude oil (CL1) closed at $68.64 a barrel on Sept. 5.

“They are really heavy in the New Mexico portion of the Permian Basin, and we think production growth will be about 10% per year,” he said.

GlaxoSmithKline

American depositary receipts of GlaxoSmithKline (GSK) closed at $40.13 and have ranged between $34.52 and $42.36 over the past year. The dividend yield is 5.36%.

The shares took a beating late last year in part because the company’s Advair asthma medication went off patent. “Starting next year they can get back to that 5% to 7% growth per year,” McIntosh said.

GlaxoSmithKline trades for 13.8 times the consensus 2018 earnings estimate among analysts polled by FactSet. McIntosh said the company’s valuation to earnings is “pretty inexpensive,” and S&P 500 pharmaceutical companies trade for a weighted 15.8 times estimated 2018 earnings.

McIntosh said the average fee paid by PVG’s private clients with money invested using the firm’s Large-Cap Value strategy is 0.93%.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Google Plus
  • Print

For more news you can use to help guide your financial life, visit our Insights page.


Copyright © 2018 Dow Jones & Company, Inc. All Rights Reserved.
Votes are submitted voluntarily by individuals and reflect their own opinion of the article's helpfulness. A percentage value for helpfulness will display once a sufficient number of votes have been submitted.
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.